Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: An observational study

Maximilian J. Hochmair, Alessandro Morabito, Desiree Hao, Cheng Ta Yang, Ross A. Soo, James C.H. Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten, Tanja Cufer

Research output: Contribution to journalArticle

31 Scopus citations


Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. Trial registration number: NCT0337077.

Original languageEnglish (US)
Pages (from-to)2861-2874
Number of pages14
JournalFuture Oncology
Issue number27
Publication statusPublished - Nov 2018



  • T790M
  • afatinib
  • osimertinib
  • sequential

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this